3 results
Objective: To demonstrate the non-inferiority of ertugliflozin compared with anon-ertugliflozin comparator group on the time to first occurrence of any of thecomponents of the composite endpoint of cardiovascular death, non-fatal…
Primary objective:To continue assessing the safety and tolerability of ANAVEX2-73.Safety and Tolerability Measures:* Physical examination* Vital signs (heart rate, respiratory rate, systolic blood pressure [SBP], diastolic blood pressure [DBP],…
Primary Objectives:* Change from baseline to week 48 in cognition according to the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog) compared to placebo.* Changes from baseline to week 48 in ability to perform daily activities according to the…